Wednesday, September 23, 2026
Opening of 2026 International Invasive Lobular Carcinoma Symposium: Welcome

Professor of Surgery, University of California San Francisco, Program Director of the UCSF Lobular Breast Cancer Research Program
Debate 1: Tumor morphology alone should be used to diagnose ILC

Professor of Pathology and Immunology, University of Washington in St. Louis, Section Head of Breast Pathology

Associate Professor of Pathology, Harvard Medical School, Chief of Cancer Pathology, Beth Israel Deaconess Medical Center, Chief of Oncologic Pathology, Dana-Farber Institute
Scientific Session 1: Genetics, Risk, and Exposures

Associate Professor, Swiss Federal Institute of Technology Lausanne (EPFL), Professor at the Institute of Cancer Research London

Associate Professor of General Surgery, European Institute of Oncology

Associate Professor, Emory University School of Medicine, Chief Surgical Officer, Winship Cancer Institute

Clinical Professor, Obstetrics and Gynecology, University of California, San Francisco,
Chief Clinical Officer at Midi Health
Scientific Session 2: The ILC Cell and Microenvironment

Distinguished University Professor, George Mason University, Co-Director, Center for Applied Proteomics and Molecular Medicine

Research Director at Institute National De La Santé Et De La Recherche Médicale (INSERM), Scientific Coordinator, Institut Curie

Professor of Oncology, Georgetown University, Associate Director of Training and Education, Lombardi Comprehensive Cancer Center

Assistant Professor, Department of Computational and Systems Biology, University of Pittsburgh, UPMC Hillman Cancer Center
Thursday, September 24, 2026
Scientific Session 3: Mechanisms of Metastasis

Professor, Cancer Genomics and Deputy Director, Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London

Distinguished Professor and Chair of Pathology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

Associate Professor, Public Health Sciences, Fred Hutchinson Cancer Center

Professor, Director of the Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco
Debate 2: Cytotoxic chemotherapy is ineffective in patients with metastatic ILC

Associate Professor of Medicine, Breast Medical Oncology Team Leader, Moores Cancer Center, University of California, San Diego

Clinical Investigator, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, Co-Director of MSK Lobular Breast Cancer Program
Scientific Session 4: Model Systems & Pathology

Professor of Pharmacology & Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh Foundation Chair, Director, Institute for Precision Medicine

Pathologist and Researcher, Institut Curie; Visiting Investigator, Memorial Sloan Kettering Cancer Center

Professor, Department of Molecular and Cellular Biology, Lester & Sue Smith Breast Center, Baylor College of Medicine

Professor, Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Associate Director for Basic Research, Case Comprehensive Cancer Center
Keynote Address 1: Hereditary CDH1 Mutations: The identification and evolution of a cancer syndrome

Professor, University of Otago, Co-Founder, Pacific Edge Ltd.
Scientific Session 5: Diagnostics and Clinical Management

Assistant Professor of Medical Oncology, University of Texas MD Anderson Cancer Center, Chair, Lobular Breast Cancer Alliance

Postdoctoral Research Fellow, Laboratory for Translational Breast Cancer Research at KU Leuven

Assistant Professor, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center

Associate Professor of Clinical Medicine, University of Pennsylvania, Director of the Rena Rowan Breast Center at Abramson Cancer Center
Scientific Session 6: Clinical Trial Results & Advocacy

Medical Oncologist, Molecular and Cellular Oncology, Dana-Farber Cancer Institute

Assistant Professor, Hematology and Oncology, Vanderbilt University Medical Center

Professor and Lead Senior Physician, Charité Breast Center, Berlin

Professor, Baylor College of Medicine, Executive Medical Director, Dan L Duncan Comprehensive Cancer Center
Friday, September 25, 2026
Scientific Session 7: Endocrine Resistance & Novel Targets

Associate Professor, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center

Bioinformatics Researcher, Laboratory for Translational Breast Cancer Research, KU Leuven University

Professor of Experimental & Preclinical Oncology, University Medical Center Utrecht
Keynote Address 2: Novel approaches to screening and clinical trials for breast cancer: how to improve care for ILC

Director, Breast Care Center, University of California, San Francisco
Scientific Session 8: Advanced Imaging and Artificial Intelligence

Associate Professor of Radiology, Harvard Medical School, Associate Medical Director of Quality for Breast Imaging, Mass General Brigham

Assistant Attending in Radiology, Memorial Sloan Kettering Cancer Center

Assistant Professor, KU Leuven, Co-Leader of Imaging Working Group, European Lobular Breast Cancer Consortium
Dynami Foundation Leigh Pate Memorial Lecture

Professor, Univ of Pittsburgh, Co-Director, Women’s Cancer Research Center, Co-Leader Cancer Biology Program, UPMC HCC and MWRI
Scientific Session 9: SNMMI Special Session – Imaging in ILC

James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy, Hoag Family Cancer Institute, Professor, University of Southern California

Professor of Hematology & Oncology, University of Washington, Clinical Director, Breast Cancer Center, Fred Hutch Cancer Center

Radiologist, University of Wisconsin School of Medicine and Public Health

Matthew J. Wilson Professor & Vice-Chair for Research, Radiology Department, Perelman School of Medicine at the University of
Pennsylvania
Scientific Session 10: Radiotherapy, Clinical Trials

Associate Professor, Department of Pathology, University of Colorado, Anschutz Medical Campus

Assistant Professor of Oncology, KU Leuven, Head of the Laboratory for Translational Breast Cancer Research
Debate 3: Patients with ILC should be treated with neoadjuvant therapy

Medical Director, Breast Medical Oncology, University of California, San Francisco,
Helen Diller Comprehensive Cancer Center

Assistant Professor of Medicine, University of Pittsburgh School of Medicine, Magee-Womens Hospital UPMC Hillman Cancer Center